Brand Index Methodology
The Morning Consult Brand Index is an indicator of brand strength among consumers. Each Fortune 500 company receives a score based on a ratio of favorable to unfavorable impressions among U.S. adults and its overall favorability. This ensures that a score takes into account how well-liked a company is among people who have an opinion of it without penalizing companies that are not consumer-facing.
Morning Consult polls thousands of adults across the country each week. The surveys are conducted online using large, established online survey vendors. The data is weighted to approximate a nationally representative sample based on age, race/ethnicity, gender, educational attainment, region, annual household income, home ownership status and marital status.
The Thousand Oaks, Calif.-based biotech pharmaceutical company makes drugs that treat patients in nearly 100 countries.
CEO
Robert A. Bradway
CEO Title
Chairman & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Thousand Oaks, CA
Website
Years on Fortune 500 List
18
Employees
19,200
SPONSOR CENTER
| $ millions | % change | |
|---|---|---|
| Revenues ($M) | $22,991 | 6.1% |
| Profits ($M) | $7,722.0 | 11.3% |
| Assets ($M) | $77,626 | |
| Total Stockholder Equity ($M) | $29,875 | |
| Market Value — as of March 31, 2017 ($M) | $120,830 |
| Profit as % of Revenues | 33.6% | |
| Profits as % of Assets | 9.9% | |
| Profits as % of Stockholder Equity | 25.8% |
| Earnings Per Share ($) | 10.24 | |
| EPS % Change (from 2015) | 13.0% | |
| EPS % Change (5 year annual rate) | 20.4% | |
| EPS % Change (10 year annual rate) | 15.2% |
| Total Return to Investors (2016) | -7.5% | |
| Total Return to Investors (5 year, annualized) | 20.3% | |
| Total Return to Investors (10 year, annualized) | 9.1% |
- Previous Close:
- Market Cap: NaNB
- Next Earnings Date:
- High:
- Low:
- 52 Week High:
- 52 Week Low:
- 52 Week Change %: 0.00
- P/E Ratio: n/a
- EPS:
- Dividend Yield: n/a
News about Amgen
Just about everyone agrees that America's health care system is broken. Is better data—and the ability to harness it—the medicine we've been looking for?
Novartis and Amgen want to find out with an experimental drug.
The FDA approved the first cancer medicine "biosimilar" Thursday.
Scientists are ready to move an experimental treatment into phase 1 trials.
Coherus BioSciences shares took a massive hit on Monday.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc.. Dow Jones Terms & Conditions: http://www.djindexes.com/mdsidx/html/tandc/indexestandcs.html. S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions